secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dare Bioscience, Inc. (DARE)
CIK:        0001401914
Form:       8-K
Filed at:   2024-10-21T23:59:59+00:00
Accession:  0001493152-24-041796
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Daré Bioscience secures $15M common stock purchase facility with Lincoln Park Capital
--------------------------------------------------------------------------------

- Entered $15M common stock purchase agreement with Lincoln Park Capital Fund, LLC.
- Daré has sole discretion to sell up to $15M shares over 24 months; LPC obligated to buy at market-based prices.
- Proceeds intended to help fund Phase 3 program for Sildenafil Cream, 3.6% (estimated $15M direct costs).
- Issued 137,614 commitment shares to LPC; no warrants issued, no short selling permitted.
- Daré may terminate agreement at any time with no cost or penalty.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401914/000149315224041796/0001493152-24-041796-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401914/000149315224041796/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-041796

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer